<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03458819</url>
  </required_header>
  <id_info>
    <org_study_id>18-0401</org_study_id>
    <nct_id>NCT03458819</nct_id>
  </id_info>
  <brief_title>EMT in Peritoneal Dialysis Patients</brief_title>
  <official_title>Epithelial to Mesenchymal Transition (EMT) in Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 10-11% of end stage kidney disease patients worldwide utilize peritoneal&#xD;
      dialysis (PD) as their method of renal replacement therapy. Over time, the peritoneal&#xD;
      membrane often undergoes anatomic and functional changes due to the process of epithelial to&#xD;
      mesenchymal transition (EMT). EMT is characterized by increases in pro-inflammatory and&#xD;
      pro-angiogenic cytokines. In this process, the mesothelial cells lining the peritoneal&#xD;
      membrane are denuded and change their morphology to one more closely resembling fibroblasts.&#xD;
      These fibroblasts invade the submesothelial zone of the peritoneal membrane resulting in&#xD;
      marked fibrosis, and the pro-angiogenic cytokines cause an increase in neovascularization.&#xD;
      Jointly, these processes culminate in impaired function of the peritoneal membrane and often&#xD;
      limit the duration of effective PD therapy.&#xD;
&#xD;
      In vitro studies in cultured human peritoneal mesothelial cells (HPMCs) and in vivo studies&#xD;
      in rodent models of PD have demonstrated that the use of active Vitamin D receptor agonists&#xD;
      or statins may attenuate this process of EMT. These are both classes of drugs that are&#xD;
      commonly in use by patients on PD. The investigators goal is to determine whether either or&#xD;
      both of these drugs might attenuate the process of EMT in patients performing PD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will perform a standard 2 Liter overnight dwell with the usual 2.5% dextrose PD&#xD;
      solution. This will be done the night before a routinely scheduled visit to the home dialysis&#xD;
      clinic. In the clinic the fluid will be drained in usual fashion and the fluid- which would&#xD;
      otherwise be discarded- will be analyzed as below:&#xD;
&#xD;
      HPMCs will be isolated as previously described by Kinashi et al. and stored at -80 degrees&#xD;
      until analysis. Changes in the protein expression of EMT markers such as E-cadherin, alpha&#xD;
      smooth muscle actin (a-SMA), Snail, and fibronectin in the HPMCs will be evaluated by Western&#xD;
      blot analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2018</start_date>
  <completion_date type="Actual">May 22, 2019</completion_date>
  <primary_completion_date type="Actual">May 22, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the protein expression of EMT markers</measure>
    <time_frame>One year or at the end of the study, whichever occurs first.</time_frame>
    <description>The goal of this study is to determine whether either or both of these drugs, Vitamin D receptor agonists or statins, might attenuate the process of EMT in peritoneal mesothelial cells. Changes in the protein expression of EMT markers such as E-cadherin, a- SMA, Snail, and fibronectin in the HPMCs will be evaluated by Western blot analysis.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">22</enrollment>
  <condition>Peritoneal Dialysis Complication</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients on neither active Vitamin D or a statin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vit D</arm_group_label>
    <description>Patients on active Vitamin D but not a statin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Statin</arm_group_label>
    <description>Patients on a statin but not active Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D + Statin</arm_group_label>
    <description>Patients on both active Vitamin D and a statin</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Isolation of peritoneal mesothelial cells</intervention_name>
    <description>HPMCs will be isolated and stored at -80 degrees until analysis. Changes in the protein expression of EMT markers such as E-cadherin, a- SMA, Snail, and fibronectin in the HPMCs will be evaluated by Western blot analysis.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>D + Statin</arm_group_label>
    <arm_group_label>Statin</arm_group_label>
    <arm_group_label>Vit D</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Isolated human peritoneal mesothelial cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        PD patients &gt; 18 years old. We propose to study 4 groups of 6 patients each:&#xD;
&#xD;
          1. Patients taking neither an active Vitamin D analogue nor a statin&#xD;
&#xD;
          2. Patients already taking an active Vitamin D analogue&#xD;
&#xD;
          3. Patients already taking a statin&#xD;
&#xD;
          4. Patients already taking both an active Vitamin D analogue and a statin&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt; 18 years of age&#xD;
&#xD;
          -  Patients on Peritoneal dialysis, and&#xD;
&#xD;
          -  Patients that meet at least one of the criteria noted in the Population Description.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with Recent peritonitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isaac Teitelbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

